American scientists have developed a gene therapy in treating a form of eye disease that progressively robs people of their sight and peripheral vision before blindness develops. A study described the therapy that effectively eliminated the abnormal copy of rhodopsin, a light-sensing molecule, and then restored it with a healthy copy of the protein. Tracking the treatment effect more than eight months after delivery of the gene therapy, the researchers found the effect seemed stable and lasting. The team is currently working to move the findings into clinical trials.